Wellstar International enters into financing agreement with JMJ Financial

NewsGuard 100/100 Score

Wellstar International, Inc. (OTCBB:WLSI), has announced that it has entered into a financing agreement with JMJ Financial to provide the Company with an expected $1.2 million dollars in operational funding over the eighteen months. Details of the financing were contained in the Company's Form 8-K filing with the Securities and Exchange Commission on October 9, 2009.

The initial funding has been transferred to Wellstar and is expected to continue on a monthly basis. This funding will allow Wellstar to continue to operate in the near future and develop the completion of its Trillennium Medical Imaging System for rollout to the medical community. Although we have entered into a definitive agreements with respect to the financing with JMJ Financial, we cannot provide any guarantee that the funding outlined in the agreements will continue on a monthly basis or at all.

Wellstar International, Inc. seeks to be the first-to-market in deep tissue injury and pressure ulcer detection using its proprietary infrared imaging system. Thermal Imaging is a low cost, noncontact, non-radioactive diagnostic screening procedure designed for clinical evaluation. In addition, thermal imaging provides an ability to track the progress of therapies being utilized in a low cost, non-invasive manner. Thermal Imaging can detect signs of pressure ulcers before they are visible with the naked eye through detection of temperature changes at the site which allows for treatment of the pressure ulcer before it erupts. The TMI system can be used to scan all new patients into hospitals and long-term care facilities prior admittance and begin treating existing wounds before they are visible.

Source:

Wellstar International, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis